SENS — Senseonics Holdings, Inc.

Senseonics Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue Growth: Q3 2025 revenue increased by 90% year-over-year to $8.1 million, driven by strong adoption of Eversense 365. U.S. revenue was $6.4 million, while international revenue was $1.7 million.
• Gross Profit: Gross profit rose to $3.5 million, reflecting improved margins from the Eversense 365 product.
• Net Loss: The net loss narrowed to $19.5 million ($0.43 per share) from $24 million ($0.77 per share) in Q3 2024.
• Cash Position: As of September 30, 2025, cash and equivalents totaled $111.3 million, with debt and accrued interest at $35.3 million.
• Full-Year Revenue Guidance: The company expects approximately $35 million in global net revenue for 2025.

2. Strategic Updates and Business Highlights

• Commercialization Transition: Senseonics signed a memorandum of understanding with Ascensia Diabetes Care to reassume control over Eversense commercialization, with plans for a full transition by January 1, 2026.
• Patient Growth: The company is on track to double the number of patients using Eversense in 2025, with a 160% increase in new patient shipments year-over-year.
• Direct-to-Consumer (DTC) Marketing: DTC efforts have significantly increased patient leads (300% year-over-year), with 60% of new patients coming from DTC advertising.
• Eon Care Expansion: The Eon Care network is becoming a key driver for insertion capacity, now representing about 25% of all insertions nationwide.
• Product Development: CE mark application for Eversense 365 in Europe is in the final review stages, with expected approval by the end of 2025.

3. Forward Guidance and Outlook

• 2026 Expectations: While specific guidance for 2026 will be provided in January, the company anticipates continued revenue growth driven by the transition to direct commercialization and expected margin improvements (projected gross margins of 50% in 2026).
• Patient Doubling Strategy: Senseonics aims to continue doubling its patient base in 2026, following the same trajectory as 2025.

4. Bad News, Challenges, or Points of Concern

• Transition Risks: The transition from Ascensia to Senseonics may pose operational challenges, particularly in managing inventory and ensuring a smooth integration of sales forces.
• Market Competition: The competitive landscape remains challenging, with significant market share held by established players like Dexcom and Abbott. The company is seeing a shift in patients from these competitors, but ongoing competitive pressures exist.
• DTC Marketing Saturation: There is potential for diminishing returns on DTC marketing investments as the company scales, necessitating careful management of advertising strategies.

5. Notable Q&A Insights

• Patient Demographics: Approximately 90% of new patients are switchers from other CGM systems, primarily from Dexcom and Libre, indicating effective targeting through DTC campaigns.
• Integration with Sequel's Twiist: Expected to begin early in Q1 2026, with ramp-up dependent on pump availability. The integration is viewed as a significant growth driver for the company.
• Reimbursement Trends: The company is experiencing a positive shift in private payer reimbursement policies, which may enhance access and adoption of Eversense products.
• DTC Spend: DTC marketing expenditures are expected to remain consistent in 2026, with a focus on targeted campaigns to maximize patient acquisition.

Overall, Senseonics reported strong growth in Q3 2025, driven by the Eversense 365 product, while navigating the complexities of transitioning commercialization and managing competitive pressures.